Similar articles for PMID: 32169910

Year	Number of Results
2014	1
2015	3
2016	21
2017	27
2018	21
2019	32
2020	32
2021	33
2022	13
2023	3
2024	0

1

Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study.

Derlin T, Werner RA, Lafos M, Henkenberens C, von Klot CAJ, Sommerlath Sohns JM, Ross TL, Bengel FM. Derlin T, et al. J Nucl Med. 2020 Nov;61(11):1602-1606. doi: 10.2967/jnumed.120.241588. Epub 2020 Mar 13. J Nucl Med. 2020. PMID: 32169910 Free article.

2

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving ¹⁷⁷Lu-PSMA-617 Radioligand Therapy.

Kessel K, Seifert R, Weckesser M, Roll W, Humberg V, Schlack K, Bögemann M, Bernemann C, Rahbar K. Kessel K, et al. Theranostics. 2020 Jun 18;10(17):7645-7655. doi: 10.7150/thno.44556. eCollection 2020. Theranostics. 2020. PMID: 32685010 Free PMC article.

3

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with ¹⁷⁷Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.

Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, Gafita A, Wester HJ, Gschwend JE, Weber WA, Schwaiger M, Knorr K, Eiber M. Heck MM, et al. Eur Urol. 2019 Jun;75(6):920-926. doi: 10.1016/j.eururo.2018.11.016. Epub 2018 Nov 22. Eur Urol. 2019. PMID: 30473431

4

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.

Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ. Baum RP, et al. J Nucl Med. 2016 Jul;57(7):1006-13. doi: 10.2967/jnumed.115.168443. Epub 2016 Jan 21. J Nucl Med. 2016. PMID: 26795286 Free article.

5

The value of tumor markers in men with metastatic prostate cancer undergoing [¹⁷⁷ Lu]Lu-PSMA therapy.

Yordanova A, Linden P, Hauser S, Feldmann G, Brossart P, Fimmers R, Essler M, Holdenrieder S, Ahmadzadehfar H. Yordanova A, et al. Prostate. 2020 Jan;80(1):17-27. doi: 10.1002/pros.23912. Epub 2019 Oct 3. Prostate. 2020. PMID: 31579967

6

Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing ¹⁷⁷Lu-PSMA-617 radioligand therapy.

Khreish F, Kochems N, Rosar F, Sabet A, Ries M, Maus S, Saar M, Bartholomä M, Ezziddin S. Khreish F, et al. Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):103-112. doi: 10.1007/s00259-020-04828-5. Epub 2020 May 6. Eur J Nucl Med Mol Imaging. 2021. PMID: 32378019

7

Response Prediction of ¹⁷⁷Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase.

Rathke H, Holland-Letz T, Mier W, Flechsig P, Mavriopoulou E, Röhrich M, Kopka K, Hohenfellner M, Giesel FL, Haberkorn U, Kratochwil C. Rathke H, et al. J Nucl Med. 2020 May;61(5):689-695. doi: 10.2967/jnumed.119.231431. Epub 2019 Oct 25. J Nucl Med. 2020. PMID: 31653712 Free article.

8

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for ¹⁷⁷Lu-labelled PSMA Radioligand Therapy.

Thang SP, Violet J, Sandhu S, Iravani A, Akhurst T, Kong G, Ravi Kumar A, Murphy DG, Williams SG, Hicks RJ, Hofman MS. Thang SP, et al. Eur Urol Oncol. 2019 Nov;2(6):670-676. doi: 10.1016/j.euo.2018.11.007. Epub 2018 Dec 13. Eur Urol Oncol. 2019. PMID: 31412006 Clinical Trial.

9

[PSMA-targeted radioligand therapy in prostate cancer].

Heck MM, Retz M, Tauber R, Knorr K, Kratochwil C, Eiber M. Heck MM, et al. Urologe A. 2017 Jan;56(1):32-39. doi: 10.1007/s00120-016-0274-3. Urologe A. 2017. PMID: 27885457 Review. German.

10

PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.

Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U. Kratochwil C, et al. J Nucl Med. 2016 Aug;57(8):1170-6. doi: 10.2967/jnumed.115.171397. Epub 2016 Mar 16. J Nucl Med. 2016. PMID: 26985056 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

147 results

Results by year